Klaria Pharma Holding AB (publ.) Company Description

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock.

Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection.

The company is also involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquartered in Uppsala, Sweden.

Klaria Pharma Holding AB (publ.)

Country	Sweden
Founded	2014
Industry	Pharmaceutical Preparations
Employees	4
CEO	Scott Boyer

Contact Details

Address: Virdings Allé 2 Uppsala, 754 50 Sweden
Phone	46 84 46 42 99
Website	klaria.com

Stock Details

Ticker Symbol	6FN
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2834

Key Executives

Name	Position
Scott Boyer	Chief Executive Officer
Hans Richter	Chief Financial Officer